Antagonisme < Antagoniste < Antagoniste analgésique narcotique

Facettes :

List of bibliographic references indexed by Antagoniste

Number of relevant bibliographic references: 40.
[0-20] [0 - 20][0 - 40][20-40]

Ident.	Authors (with country if any)	Title
004039 (2003)	Rajesh Pahwa [États-Unis] ; Kelly E. Lyons [États-Unis]	Mirtazapine in essential tremor: A double‐blind, placebo‐controlled pilot study
004084 (2003)	William G. Ondo [États-Unis] ; Christine Hunter [États-Unis]	Flumazenil, a GABA antagonist, may improve features of Parkinson's disease
004085 (2003)	Juha-Matti Savola [Finlande] ; Michael Hill [Royaume-Uni] ; Mia Engstrom [Finlande] ; Hannele Merivuori [Finlande] ; Siegfried Wurster [Finlande] ; Steven G. Mcguire [Royaume-Uni] ; Susan H. Fox [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni, Canada]	Fipamezole (JP‐1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa‐induced dyskinesia in the MPTP‐lesioned primate model of Parkinson's disease
004233 (2002)	Ergun Y. Uc [États-Unis] ; Gerald A. Dienel [États-Unis] ; Nancy F. Cruz [États-Unis] ; Sami I. Harik [États-Unis]	β‐Adrenergics enhance brain extraction of levodopa
004284 (2002)	Guy Arnold [Allemagne] ; Klaus Tatsch [Allemagne] ; Eduardo Kraft [Allemagne] ; Wolfgang H. Oertel [Allemagne] ; Johannes Schwarz [Allemagne]	Steele‐Richardson‐Olszewski‐Syndrome: Reduction of dopamine D2 receptor binding relates to the severity of midbrain atrophy in vivo: 123IBZM SPECT and MRI study
004303 (2002)	Johannes Schiefer [Allemagne] ; G. Bernhard Landwehrmeyer [Allemagne] ; Hans-Gerd Lüesse [Allemagne] ; Arne Sprünken [Allemagne] ; Christiane Puls [Allemagne] ; Anna Milkereit [Allemagne] ; Eva Milkereit [Allemagne] ; Christoph M. Kosinski [Allemagne]	Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease
004544 (2002)	Joanne E. Nash [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni]	Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: Intrastriatal microinjection studies in the 6‐OHDA‐lesioned rat
004622 (2002)		Drugs to treat autonomic dysfunction in Parkinson's disease
004639 (2002)		Anticholinergic therapies in the treatment of Parkinson's disease
004641 (2002)		Amantadine and other antiglutamate agents
004745 (2001)	Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Micheal P. Hill [Royaume-Uni] ; David Peggs [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni]	Neural mechanisms underlying peak‐dose dyskinesia induced by levodopa and apomorphine are distinct: Evidence from the effects of the alpha2 adrenoceptor antagonist idazoxan
004780 (2001)	Olivier Rascol [France] ; I. Arnulf [France] ; H. Peyro-Saint Paul [France] ; C. Brefel-Courbon [France] ; M. Vidailhet [France] ; C. Thalamas [France] ; A. M. Bonnet [France] ; S. Descombes [France] ; B. Bejjani [France] ; N. Fabre [France] ; J. L. Montastruc [France] ; Yves Agid [France]	Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease
004968 (2000)	Norman A. Leopold [États-Unis]	Risperidone treatment of drug‐related psychosis in patients with parkinsonism
004992 (2000)	Christopher G. Goetz [États-Unis] ; Toan Q. Vu [États-Unis] ; Paul M. Carvey [États-Unis] ; Sue Leurgans [États-Unis]	Posthypoxic myoclonus in the rat: Natural history, stability, and serotonergic influences
004A57 (2000)	Alice J. Manson [Royaume-Uni] ; Elena Iakovidou [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni]	Idazoxan is ineffective for levodopa‐induced dyskinesias in Parkinson's disease
004B73 (2000)	Hasmet A. Hanagasi [Turquie] ; Gülüstü Kaptanoglu [Turquie] ; Hüseyin A. Sahin [Turquie] ; Murat Emre [Turquie]	The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa
004C14 (1999)	Jörg Wissel [Autriche] ; Jörg Müller [Autriche] ; Georg Ebersbach [Autriche] ; Werner Poewe [Autriche]	Trick maneuvers in cervical dystonia: Investigation of movement‐ and touch‐related changes in polymyographic activity
004C29 (1999)	Sybille Spieker [Allemagne] ; Peter-Andreas Löschmann [Allemagne] ; Thomas Klockgether [Allemagne]	The NMDA antagonist budipine can alleviate levodopa‐induced motor fluctuations
004C50 (1999)	H. Diana Rosas [États-Unis] ; Walter J. Koroshetz [États-Unis] ; Bruce G. Jenkins [États-Unis] ; Y. Iris Chen ; Douglas L. Hayden [États-Unis] ; M. Flint Beal [États-Unis] ; Merit E. Cudkowicz [États-Unis]	Riluzole therapy in Huntington's disease (HD)
004C58 (1999)	Anette Schrag [Royaume-Uni] ; Ludwig Schelosky [Allemagne] ; Udo Scholz [Allemagne] ; Werner Poewe [Autriche]	Reduction of parkinsonian signs in patients with Parkinson's disease by dopaminergic versus anticholinergic single‐dose challenges
004E36 (1999)	B. Henry [Royaume-Uni] ; S. H. Fox [Royaume-Uni] ; D. Peggs [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; J. M. Brotchie [Royaume-Uni]	The α2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-Parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/PascalFr.i -k "Antagoniste" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/PascalFr.i  \
                -Sk "Antagoniste" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    PascalFr.i
   |clé=    Antagoniste
}}

---

This area was generated with Dilib version V0.6.23. Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024